Cargando…
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF(V600E) mutation
Liquid biopsies from cancer patients have the potential to improve diagnosis and prognosis. The assessment of surrogate markers of tumor progression in circulating extracellular vesicles could be a powerful non-invasive approach in this setting. We have characterized extracellular vesicles purified...
Autores principales: | García-Silva, Susana, Benito-Martín, Alberto, Sánchez-Redondo, Sara, Hernández-Barranco, Alberto, Ximénez-Embún, Pilar, Nogués, Laura, Mazariegos, Marina S., Brinkmann, Kay, Amor López, Ana, Meyer, Lisa, Rodríguez, Carlos, García-Martín, Carmen, Boskovic, Jasminka, Letón, Rocío, Montero, Cristina, Robledo, Mercedes, Santambrogio, Laura, Sue Brady, Mary, Szumera-Ciećkiewicz, Anna, Kalinowska, Iwona, Skog, Johan, Noerholm, Mikkel, Muñoz, Javier, Ortiz-Romero, Pablo L., Ruano, Yolanda, Rodríguez-Peralto, José L., Rutkowski, Piotr, Peinado, Héctor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504207/ https://www.ncbi.nlm.nih.gov/pubmed/30975894 http://dx.doi.org/10.1084/jem.20181522 |
Ejemplares similares
-
Correction: Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and BRAF(V600E) mutation
por: García-Silva, Susana, et al.
Publicado: (2019) -
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism.
por: García-Silva, Susana, et al.
Publicado: (2021) -
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF (V600) Mutation-Positive Melanoma
por: Czarnecka, Anna M., et al.
Publicado: (2021) -
Selection of Ceratitis capitata (Diptera: Tephritidae) Specific Recombinant Monoclonal Phage Display Antibodies for Prey Detection Analysis
por: Monzó, César, et al.
Publicado: (2012) -
Denosumab in Giant Cell Tumor of Bone: Multidisciplinary Medical Management Based on Pathophysiological Mechanisms and Real-World Evidence
por: Borkowska, Aneta Maria, et al.
Publicado: (2022)